CompletedPhase 2NCT01531673
Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation
Studying Congenital pulmonary airway malformation
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Principal Investigator
- Scott Donaldson, MDUniversity of North Carolina
- Intervention
- VX-661(drug)
- Enrollment
- 194 target
- Eligibility
- 12 years · All sexes
- Timeline
- 2012 – 2014
Study locations (30)
- Vertex Investigational Site, Birmingham, Alabama, United States
- Vertex Investigational Site, Oakland, California, United States
- Vertex Investigational Site, Boise, Idaho, United States
- Vertex Investigational Site, Chicago, Illinois, United States
- Vertex Investigational Site, Boston, Massachusetts, United States
- Vertex Investigational Site, Grand Rapids, Michigan, United States
- Vertex Investigational Site, Kansas City, Missouri, United States
- Vertex Investigational Site, Long Branch, New Jersey, United States
- Vertex Investigational Site, New Hyde Park, New York, United States
- Vertex Investigational Site, Chapel Hill, North Carolina, United States
- Vertex Investigational Site, Cincinnati, Ohio, United States
- Vertex Investigational Site, Columbus, Ohio, United States
- Vertex Investigational Site, Oklahoma City, Oklahoma, United States
- Vertex Investigational Site, Hershey, Pennsylvania, United States
- Vertex Investigational Site, Pittsburgh, Pennsylvania, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01531673 on ClinicalTrials.govOther trials for Congenital pulmonary airway malformation
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07569419Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic FibrosisUniversity of Nottingham
- RECRUITINGNANCT06132048A Usability Validation of the MuCopilot Mobile Application, a Digital Tool for the Unsupervised Objective Assessment of Cystic FibrosisAd scientiam
- ACTIVE NOT RECRUITINGNCT06371261Pathogenicity of Species of the Achromobacter Genus in Patients From Reunion Island With Cystic FibrosisCentre Hospitalier Universitaire de la Réunion
- RECRUITINGNANCT06302985Atomized Inhalation ICG for Treatment of Congenital Lung MalformationsJiexiong Feng
- ACTIVE NOT RECRUITINGNCT07568119Feasibility and Acceptance of SonoHeal for Airway Clearance and Preliminary Comparison With the Standard of CareCognita Labs LLC
- RECRUITINGPHASE1NCT05504837A Study Assessing KB407 for the Treatment of Cystic FibrosisKrystal Biotech, Inc.
- RECRUITINGNANCT05701514The COllaborative Neonatal Network for the First CPAM TrialErasmus Medical Center
- ACTIVE NOT RECRUITINGPHASE3NCT05444257A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination TherapyVertex Pharmaceuticals Incorporated
See all trials for Congenital pulmonary airway malformation →